Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Echo Therapeutics Inc    

ECHO THERAPEUTICS INC
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Echo Therapeutics : Announces Second Quarter 2016 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/15/2016 | 07:35pm CEST

Aug 12, 2016

ISELIN, N.J., Aug. 12, 2016/PRNewswire/ - Echo Therapeutics, Inc. (OTCQB: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the quarter ended June 30, 2016. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, may be accessed on the SEC's website, www.sec.gov.

Second Quarter 2016 Financial Results

Echo's net loss to common shareholders for the second quarter of 2016 was $9.4 million, or ($0.82)per share, compared to $10.8 million, or ($0.97)per share, for the second quarter of 2015. The operating loss for the second quarter of 2016 was $1.5 millioncompared to $12.3 millionfor the second quarter of 2015. The 2015 second quarter operating loss was significantly impacted by a one-time $9.6 millionimpairment charge for the Company's Azone intangibles. Research and development (R&D) expenses were $0.7 millionfor both the second quarter of 2016 and 2015. Selling, general and administrative (S,G&A) expenses were $0.8 millionduring the second quarter of 2016 compared to $1.5 millionduring the second quarter of 2015. The decrease in S,G&A expenses was primarily due to a decline in legal fees.

Recent Corporate Highlights:

  • On May 3, 2016, Echo closed the second tranche of the January 29, 2016Securities Purchase Agreement with certain institutional and other accredited investors and issued Notes in an aggregate principal amount of $3,361,620.
  • In June 2016, Echo began stand-alone and integrated testing of its NextGen CGM prototype components. Rigorous testing of each component independently and as an integrated system will continue as the Company optimizes its system in preparation for future clinical and regulatory trials. Echo began hardware and software testing of the NextGen Exfoliator and the Bluetooth transmitter.
  • In June 2016, Echo received Institutional Review Board (IRB) approval for a new clinical protocol. The new protocol allows expanded testing of the Company's CGM system and now permits Echo to recruit both pediatric and adult subjects for its internal and external studies.
  • In June 2016, Echo selected a Clinical Research Organization (CRO) for the development of a comprehensive regulatory and clinical strategy for its CGM system. The CRO has a demonstrated track record of successfully designing and managing clinical trials.
  • A new patent entitled 'Transdermal Analyte Monitoring System and Methods for Analyte Detection' was granted by Japan(Application number 2013-169786) covering Echo's system and methods for transdermal monitoring of analytes, including glucose and other substances. The patent describes a system utilizing a sensor and a hydrogel with a specific formulation that work together to allow detection of glucose, lactate or other substances.

'Progress on the development of our NextGen CGM continued during the second quarter with the selection of our CRO and the start of stand-alone and integrated testing of the system components,' said Scott W. Hollander, Echo's President and CEO. 'We look forward to providing an update of additional advancements and the regulatory and commercialization plan in Chinain the near term.'

About Echo Therapeutics

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company's CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's CGM System, the failure of future development and preliminary marketing efforts related to Echo's CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell Echo's CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(732) 201-4189

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Echo Therapeutics Inc. published this content on 12 August 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 August 2016 17:35:05 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ECHO THERAPEUTICS INC
2016ECHO THERAPEUTICS : Announces Second Quarter 2016 Financial Results
PU
2016ECHO THERAPEUTICS : Begins Testing of NextGen CGM System Components
PU
2016ECHO THERAPEUTICS : Announces Institutional Review Board (IRB) Approval of New P..
PU
2016ECHO THERAPEUTICS : Announces Final Closing of Private Placement of $5.1 Million..
PU
2016ECHO THERAPEUTICS : Announces Voting Results of Special Meeting of Stockholders
PU
2016ECHO THERAPEUTICS : Announces New Patents for Non-Invasive Sensing Technology
PU
2015ECHO THERAPEUTICS : Announces Third Quarter 2015 Financial Results and Provides ..
PU
2014ECHO THERAPEUTICS : Leading Independent Proxy Advisory Firm Glass Lewis Recommen..
PU
2014ECHO THERAPEUTICS : Schedules First Quarter 2014 Financial Results and Regulator..
PU
2013ECHO THERAPEUTICS INC : TrendingWallStreet.com Starts Volume Coverage on ECTE, A..
AC
More news
News from SeekingAlpha
2017Echo Therapeutics in a bind over high-cost debt 
2016District court rules in favor of Echo Therapeutics 
2016Echo Therapeutics target of whistleblower suit, survival at stake; shares dow.. 
2016Echo Therapeutics auditor quits; shares down 14% 
2016Echo Therapeutics reports Q2 results 
Chart ECHO THERAPEUTICS INC
Duration : Period :
Echo Therapeutics Inc Technical Analysis Chart | US27876L2060 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Alan Wayne Schoenbart Chief Executive Officer, CFO, Secretary & Director
Christine H. Olimpio Director-Investor Relations & Communications
Sector and Competitors
1st jan.Capitalization (M$)
ECHO THERAPEUTICS INC-72.22%0
THERMO FISHER SCIENTIFIC13.70%86 857
DANAHER CORPORATION9.18%70 780
INTUITIVE SURGICAL25.03%51 587
BOSTON SCIENTIFIC CORPORATION16.54%39 785
ROYAL PHILIPS4.41%38 068